The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chulkova S.V.

N.N. Blokhin National Medical Research Center of Oncology;
N.I. Pirogov Russian National Research Medical University

Loginov V.I.

Institute of General Pathology and Pathophysiology

Podluzhny D.V.

Blokhin National Medical Research Center of Oncology

Egorova A.V.

N.I. Pirogov Russian National Research Medical University

Syskova A.Yu.

N.I. Pirogov Russian National Research Medical University

Semichev D.G.

N.I. Pirogov Russian National Research Medical University

Gladilina I.A.

N.N. Blokhin National Medical Research Center of Oncology;
N.I. Pirogov Russian National Research Medical University

Kudashkin N.E.

Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

The role of molecular genetic factors in the development of cholangiocellular carcinoma

Authors:

Chulkova S.V., Loginov V.I., Podluzhny D.V., Egorova A.V., Syskova A.Yu., Semichev D.G., Gladilina I.A., Kudashkin N.E.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2022;84(3): 76‑83

DOI: 10.17116/patol20228403176

Views: 1807

Downloaded: 88

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF MOLECULAR GENETIC FACTORS IN THE DEVELOPMENT OF CHOLANGIOCELLULAR CARCINOMA
THE ROLE OF MOLECULAR GENETIC FACTORS IN THE DEVELOPMENT OF CHOLANGIOCELLULAR CARCINOMA

To cite this article:

Chulkova SV, Loginov VI, Podluzhny DV, et al. . The role of molecular genetic factors in the development of cholangiocellular carcinoma. Russian Journal of Archive of Pathology. 2022;84(3):76‑83. (In Russ.)
https://doi.org/10.17116/patol20228403176

Подписка 2025-2 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata
Recommended articles:
Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papi­llary muci­nous tumor asso­ciated with ductal adenocarcinoma of the pancreatic tail. Piro­gov Russian Journal of Surgery. 2024;(8):57-63
Repeated liver rese­ctions for recu­rrent intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(9):30-37

The article lists the main inducers of cholangiocarcinogenesis. The main inflammatory mediators (IL-6, nitric oxide, COX2) have been considered. Data on the study of gene mutations in cholangiocarcinomas are presented. The spectrum of genetic mutations depends on the biliary cancer origin (FGFR2 with intrahepatic cholangiocarcinoma, PRKACA, PRKACB with extrahepatic cholangiocarcinoma). Mutations in the KRAS, TP53, ARIAD1A genes are common in extrahepatic bile duct cancer. The role of epigenetic changes such as DNA hypermethylation, histone modifications, chromatin remodeling, as well as disturbances in miRNA expression is presented. A number of epigenetic features, such as the presence of a TP53 mutations with hypermethylation of p14ARF, DAPK, and/or ASC, correlate with a more aggressive course of the disease. The role of the SOX17 gene in the development of drug resistance is highlighted. The study of the molecular genetic features of extrahepatic bile duct cancer can help to better understand the pathogenesis of this type of tumor, to establish new prognostic and diagnostic markers of the disease.

Keywords:

cholangiocarcinoma
molecular and genetic factors
epigenetic factors

Authors:

Chulkova S.V.

N.N. Blokhin National Medical Research Center of Oncology;
N.I. Pirogov Russian National Research Medical University

Loginov V.I.

Institute of General Pathology and Pathophysiology

Podluzhny D.V.

Blokhin National Medical Research Center of Oncology

Egorova A.V.

N.I. Pirogov Russian National Research Medical University

Syskova A.Yu.

N.I. Pirogov Russian National Research Medical University

Semichev D.G.

N.I. Pirogov Russian National Research Medical University

Gladilina I.A.

N.N. Blokhin National Medical Research Center of Oncology;
N.I. Pirogov Russian National Research Medical University

Kudashkin N.E.

Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University

Received:

02.02.2022

Accepted:

10.03.2022

List of references:

  1. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185.  https://doi.org/10.1186/s12885-019-5391-0
  2. Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, Vaquero J, Marin JJG, Coulouarn C. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39(suppl 1):43-62.  https://doi.org/10.1111/liv.14102
  3. Gurmikov BN, Kovalenko YuA, Vishnevsky VA, Chzhao AV. Molecular genetic aspects of intrahepatic cholangiocarcinoma:literature review. Advances in Molecular Oncology=Uspechi molekulyarnoi onkologii.2019;6(1):37-43. (In Russ.). https://doi.org/10.17650/2313-805X-2019-6-1-37-43
  4. https://doi.org/10.24060/2076-3093-2017-7-3-60-67  https://doi.org/10.24060/2076-3093-2017-7-3-60-67
  5. Wang Y, Wan M, Zhou Q, Wang H, Wang Z, Zhong X, Zhang L, Tai S, Cui Y. The Prognostic role of SOCS3 and A20 in human cholangiocarcinoma. PLoS One. 2015;10(10):e0141165. https://doi.org/10.1371/journal.pone.0141165
  6. Jiang K, Centeno BA. Primary liver cancers, Part 2: Progression pathways and carcinogenesis. Cancer Control. 2018;25(1): 1073274817744658. https://doi.org/10.1177/1073274817744658
  7. Andresen K1, Boberg KM, Vedeld HM, Honne H, Hektoen M, Wadsworth CA, Clausen OP, Karlsen TH, Foss A, Mathisen O, Schrumpf E, Lothe RA, Lind GE. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics. 2012;7(11):1249-1257. https://doi.org/10.4161/epi.22191
  8. Tshering G, Dorji PW, Chaijaroenkul W, Na-Bangchang K. Biomarkers for the diagnosis of cholangiocarcinoma: A systematic review. Am J Trop Med Hyg. 2018;98(6):1788-1797. https://doi.org/10.4269/ajtmh.17-0879
  9. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7(6):454-465.  https://doi.org/10.1038/nri2093
  10. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010;51(3):881-890.  https://doi.org/10.1002/hep.23381
  11. Tadlock L. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology. 2001;33(1):43-51.  https://doi.org/10.1053/jhep.2001.20676
  12. Roy S, Glaser S, Chakraborty S. Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms. Front Med (Lausanne). 2019;6:293.  https://doi.org/10.3389/fmed.2019.00293
  13. Brito AF, Abrantes AM, Encarnação JC, Tralhão JG, Botelho MF. Cholangiocarcinoma: from molecular biology to treatment. Med Oncol. 2015;32(11):245.  https://doi.org/10.1007/s12032-015-0692-x
  14. Shimura T, Shibata M, Gonda K, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Marubashi S, Kono K, Takenoshita S. Clinical significance of soluble intercellular adhesion molecule-1 and interleukin-6 in patients with extrahepatic cholangiocarcinoma. J Invest Surg. 2018;31(6):475-482.  https://doi.org/10.1080/08941939.2017.1358310
  15. Sirica A. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14(46):7033. https://doi.org/10.3748/wjg.14.7033
  16. Pellat A, Vaquero J, Fouassier L. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. Hepatology. 2018;67(2):762-773.  https://doi.org/10.1002/hep.29350
  17. Jaiswal M, LaRusso N, Shapiro R, Billiar T, Gores G. Nitric oxide—mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology. 2001;120(1):190-199.  https://doi.org/10.1053/gast.2001.20875
  18. Wei J, Wang B, Wang H, Meng L, Zhao Q, Li X, Xin Y, Jiang X. Radiation-induced normal tissue damage: oxidative stress and epigenetic mechanisms. Oxid Med Cell Longev. 2019;2019:3010342. https://doi.org/10.1155/2019/3010342
  19. Wu WR, Zhang R, Shi XD, Zhu MS, Xu LB, Zeng H, Liu C. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. Oncol Rep. 2014;31:2515-2524. https://doi.org/10.3892/or.2014.3123
  20. Lee H, Wang K, Johnson A, Jones DM, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Javle M, Ross JS. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016;69(5):403-408.  https://doi.org/10.1136/jclinpath-2015-203394
  21. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003-1010. https://doi.org/10.1038/ng.3375
  22. Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P3, D’Onofrio M, Iacono C, Scarpa A, Guglielmi A. Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol. 2016;23(5):1699-1707. https://doi.org/10.1245/s10434-015-5046-6
  23. Roos E, Soer EC, Klompmaker S, Meijer LL, Besselink MG, Giovannetti E, Heger M, Kazemier G, Klümpen HJ, Takkenberg RB, Wilmink H, Würdinger T, Dijk F, van Gulik TM, Verheij J, van de Vijver MJ. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Crit Rev Oncol Hematol. 2019;140:8-16.  https://doi.org/10.1016/j.critrevonc.2019.05.011
  24. Kim BH, Cho NY, Shin SH, Kwon HJ, Jang JJ, Kang GH. CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma. Virchows Arch. 2009;455(4):343-351.  https://doi.org/10.1007/s00428-009-0829-4
  25. Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol. 2008;215(2):175-183.  https://doi.org/10.1002/path.2345
  26. Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann-Heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, et al. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. Int J Cancer. 2019;144(11):2782-2794. https://doi.org/10.1002/ijc.32026
  27. Kongpetch S, Jusakul A, Ong CK, Lim WK, Rozen SG, Tan P, Teh BT. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. Best Pract Res Clin Gastroenterol. 2015;29(2): 233-244.  https://doi.org/10.1016/j.bpg.2015.02.002
  28. Xiaofang L, Kun T, Shaoping Y, Zaiqiu W, Hailong S. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma. World J Surg Oncol. 2012;10:5.  https://doi.org/10.1186/1477-7819-10-5
  29. Merino-Azpitarte M, Lozano E, Perugorria MJ, Esparza-Baquer A, Erice O, Santos-Laso Á, O’Rourke CJ, Andersen JB, Jiménez-Agüero R, Lacasta A, D’Amato M, Briz Ó, Jalan-Sakrikar N, Huebert RC, Thelen KM, et al SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J Hepatol. 2017;67(1):72-83.  https://doi.org/10.1016/j.jhep.2017.02.017
  30. Chulkova SV, Rjabchikov DA, Dudina IA, Kazakov AM, Egorova AV, Titov KS, Hagazheeva MN, Gladilina IA, Galaeva ZM, Lepkova NV, Tupicyn NN. The prospects for the use of microRNA as diagnostic and prognostic melanoma biomarkers. Russian Journal of Biotherapy=Rossiiskii bioterapevticheskii zhurnal. 2019;18(4):51-56. (In Russ.). https://doi.org/10.17650/1726-9784-2019-18-4-51-56
  31. Ryabchikov DA, Abdullaeva EI, Dudina IA, Chulkova SV, Denchik DA, Chkhikvadze NV, Talipov OA, Vorotnikov IK. The role of micro-RNA in cancerogenesis and breast cancer prognosis. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii Minzdrava Rossii. 2018;18(2):5. (In Russ.). https://vestnik.rncrr.ru/vestnik/v18/docs/ryabchikov.pdf
  32. Ryabchikov DA, Chulkova SV, Talipov OA, Vorotnikov IK, Kazakov AM, Osipova AA, Berdova FK. Results of microRNA gene methylation analysis in different breast cancer subtypes. Oncogynecology=Onkoginekologiya. 2020;(3):4-14. (In Russ.). https://osors.ru/oncogynecology/JurText/j2020_3/03_20_04.pdf
  33. Talipov OA, Ryabchikov DA, Chulkova SV, Vorotnikov IK, Kazakov AM, Loginov VI, Kazubskaya TP, Vinokurov MS, Osipova AA, Berdova FK. Methylation of suppressor microRNA genes in breast cancer. Oncogynecology=Onkoginekologiya. 2020;(2):14-22. (In Russ.). https://osors.ru/oncogynecology/JurText/j2020_2/02_20_15.pdf
  34. Hill MA, Alexander WB, Guo B, Kato Y, Patra K, O’Dell MR, McCall MN, Whitney-Miller CL, Bardeesy N, Hezel AF. Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma. Cancer Res. 2018;78(16):4445-1.  https://doi.org/10.1158/0008-5472.CAN-17-1123
  35. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2007;27(3):378-386.  https://doi.org/10.1038/sj.onc.1210648
  36. Fernández-Barrena M, Perugorria M, Banales J. Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis. Gut. 2016;66(7):1177-1178. https://doi.org/10.1136/gutjnl-2016-312899
  37. Wangyang Z, Daolin J, Yi X, Zhenglong L, Lining H, Yunfu C, Xingming J. NcRNAs and cholangiocarcinoma. J Cancer. 2018; 9(1):100-107.  https://doi.org/10.7150/jca.21785
  38. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017;66(5):952-961.  https://doi.org/10.1016/j.jhep.2017.01.010
  39. O’Rourke CJ, Lafuente-Barquero J, Andersen JB. Epigenome remodeling in cholangiocarcinoma. Trends Cancer. 2019;5(6):335-350.  https://doi.org/10.1016/j.trecan.2019.05.002
  40. Weber J, Öllinger R, Friedrich M, Ehmer U, Barenboim M, Steiger K, Heid I, Mueller S, Maresch R, Engleitner T, Gross N, Geumann U, Fu B, Segler A, Yuan D, et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci USA. 2015;112(45):13982-13987. https://doi.org/10.1073/pnas.1512392112
  41. Zhao S, Xu Y, Wu W, Wang P, Wang Y, Jiang H and Zhu J. ARID1A variations in cholangiocarcinoma: clinical significances and molecular mechanisms. Front Oncol. 2021;11:693295. https://doi.org/10.3389/fonc.2021.693295
  42. Sasaki M, Nitta T, Sato Y, Nakanuma Y. Loss of ARID1A expression presents a novel pathway of carcinogenesis in biliary carcinomas. Am J Clin Pathol. 2016;145(6):815-825.  https://doi.org/10.1093/ajcp/aqw071
  43. Morine Y, Shimada M, Iwahashi S, Utsunomiya T, Imura S, Ikemoto T, Mori H, Hanaoka J, Miyake H. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. Surgery. 2012;151(3):412-419.  https://doi.org/10.1016/j.surg.2011.07.038
  44. Gradilone S, Radtke B, Bogert P, Huang B, Gajdos G, LaRusso N. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013;73(7):2259-2270. https://doi.org/10.1158/0008-5472.can-12-2938
  45. Pant K, Peixoto E, Richard S, Gradilone SA. Role of histone deacetylases in carcinogenesis: potential role in cholangiocarcinoma. Cells. 2020;9(3):780.  https://doi.org/10.3390/cells9030780
  46. Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Chikamoto A, Watanabe M, Beppu T, Baba H. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 2013;20(suppl 3):667-675.  https://doi.org/10.1245/s10434-013-3135-y

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.